Appointment of Director
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
21 November 2024
Biome confirms appointment of healthcare sector leader Geoffrey Sam OAM to Board of
Directors
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is
pleased to confirm the appointment of Geoffrey Sam OAM to Biome Australia’s Board of Directors
as Non-Executive Director.
With a proven track record in both growth and developed businesses spanning private and public,
Geoff brings a wealth of experience to Biome and adds significant industry-specific strength to the
board. Geoff is a top five shareholder in Biome Australia and has been for more than five years.
Building from his background in hospital executive leadership, Geoff co-founded Healthecare
Australia Pty Ltd in 2005. Healthecare Australia is a privately owned healthcare company comprising
a portfolio of 17 private hospitals and employing nearly 5,000 healthcare professionals nationwide.
He currently serves as a Non-Executive Director of IDT Ltd, Change Financial Ltd and EarlyPay Ltd.
His past board positions include ParagonCare Ltd, Money 3 Ltd, Hutchinsons Childcare Services Ltd
and Nova Health Ltd.
With decades of executive and board-level experience in healthcare, Geoff’s qualifications include a
Bachelor of Commerce (Accounting and Finance, UNSW), Master of Health Administration (UNSW)
and a Master of Arts (Economics and Social Studies, University of Manchester). Geoffrey is also a
Fellow of the Australian Institute of Company Directors.
Geoff will support Biome’s management team with creating new opportunities within the
healthcare industry to support the ongoing commercial development of Biome’s Activated
Probiotics. He will also provide guidance as the company embarks on the process of optimising its
manufacturing processes to support growth locally and abroad.
As a Non-Executive Director on the Biome Australia Board of Directors, Geoff’s end-to-end
experience in the healthcare sector will be integral to Biome’s next phase of growth.
Biome Australia’s Chairman, Ilario Faenza said “I am pleased to welcome Geoffrey to the Board of
Biome Australia. Geoff, brings a wealth of experience and expertise that will support Biome on its
growth journey, as a significant Australian healthcare company.”
Following the confirmation of his appointment to Biome Australia’s Board of Directors, Geoff Sam
said, “I am thrilled to be joining the Biome Board and being able to offer my support and guidance to
Blair and the management team. Biome is doing a fantastic job already in commercialising critically
important probiotic medicines. I will use my skills, relationship and years of experience to help Biome
achieve its goals and mission as it continues in its exciting growth journey. As a significant
shareholder in Biome, I feel well aligned to the shareholder base and feel confident about what lies
ahead.”
-ENDSApproved for release by the Biome Australia Board of Directors
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live
biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research.
Biome aims to improve health outcomes and quality of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the
world's leading organisations in microbiome research and development, Biome produced several unique live
biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and
efficacy to create its flagship range of complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated
Probiotics help prevent and support the management of various health concerns, including low mood and
sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is
committed to educating health professionals on the newfound systemic health effects of the gut microbiota,
helping them to provide innovative, evidence-based natural medicines for the management of some of
humanity's most prevalent and chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Jo Power
+61 (3) 9017 5800
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Forward looking statements
This release may contain forward looking statements, including but not limited to projections, guidance on future revenues,
earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or
guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed
or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking
Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to
place undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward
Looking Statements containing forward looking financial information provided in this release is for illustrative purposes
only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.
Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is
made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this
release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any
additional or updated information whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no
representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of
information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking
Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the
information in this release or any part of it, or that this release contains all material information about Biome or which a
prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in
Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the
current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.
Share your feedback
Discover